Puma Biotechnology (PBYI) Asset Utilization Ratio (2018 - 2026)
Puma Biotechnology's (PBYI) quarterly Asset Utilization Ratio came in at 1.11 in Q1 2026, down 2.25% YoY from 1.14 in Q1 2025, and up 1.95% on a QoQ basis from 1.09 in Q4 2025.
Puma Biotechnology (PBYI) Asset Utilization Ratio (2018 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 9 years of Asset Utilization Ratio data on file, last reported at 1.11 in Q1 2026.
- Quarterly Asset Utilization Ratio fell 2.25% year-over-year to 1.11 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.11 (down 2.25% YoY) and the FY2025 annual result came in at 1.06, up 2.37% from the prior year.
- Asset Utilization Ratio improved to 1.11 in Q1 2026, from 1.09 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 1.27 in Q2 2023 to a low of 0.94 in Q1 2022.
- A 5-year average of 1.12 and a median of 1.11 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio soared 30.8% — and 2024, when it fell 17.71%.
- Tracing PBYI's Asset Utilization Ratio over 5 years: stood at 1.19 in 2022, then dropped by 8.63% to 1.09 in 2023, then slipped by 2.18% to 1.06 in 2024, then grew by 2.61% to 1.09 in 2025, then climbed by 1.95% to 1.11 in 2026.
- The last three Asset Utilization Ratio figures came in at 1.11 (Q1 2026), 1.09 (Q4 2025), and 1.07 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 1.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.20 |
| Mar 31, 2026 | 1.11 |
| Dec 31, 2025 | 1.09 |
| Sep 30, 2025 | 1.07 |
| Jun 30, 2025 | 1.22 |
| Mar 31, 2025 | 1.14 |
| Dec 31, 2024 | 1.06 |
| Sep 30, 2024 | 1.14 |
| Jun 30, 2024 | 1.05 |
| Mar 31, 2024 | 1.02 |
| Dec 31, 2023 | 1.09 |
| Sep 30, 2023 | 1.24 |
| Jun 30, 2023 | 1.27 |
| Mar 31, 2023 | 1.23 |
| Dec 31, 2022 | 1.19 |
| Sep 30, 2022 | 1.11 |
| Jun 30, 2022 | 1.05 |
| Mar 31, 2022 | 0.94 |
| Dec 31, 2021 | 1.12 |
| Sep 30, 2021 | 1.03 |